In this article, we discuss 11 Best Falling Stocks to Buy According to Analysts.

Over the past two years, bulls have been in control, pushing US markets to new heights with each pullback. Major indices rallied to record highs as artificial intelligence emerged as a key investment theme, especially in the technology sector. Stocks also rallied amid expectations that the US Federal Reserve will cut interest rates on inflationary pressures subsiding significantly. The rally to record highs saw valuations get out of hand beyond historical norms.

A change of administration and policies in the US was always going to be the catalyst to sway investors to exit risky bets amid the premium valuations. Donald Trump’s taking over, waging a trade war against allies, and imposing stringent tariffs on imports into the US is the latest headwind that is sending US equity markets lower.

The S&P 500 is already down by about 6%, and the tech-heavy NASDAQ is down by about 8%. The pullbacks come on growing concerns that the tariff war fuelled by Trump could plunge the global economy into recession. Similarly, there are growing fears that the US Federal Reserve will refrain from cutting interest rates as inflationary pressures show signs of edging higher.

Consequently, the US equity market remains on edge, with stocks exposed to the tariff war pulling back by double-digit percentage points. The uncertainty around President Trump’s tariffs and policies is sure to heighten volatility in the markets, as was the case in his first term.

Trump’s announcement of tariffs on Chinese imports in 2018 and 2019 caused stocks to perform poorly, according to data from economists at the Federal Reserve Bank of New York. Fast forward, we are seeing a repeat of similar performance in 2025, but on a larger scale.

Nevertheless, a falling stock market will always present unique investment opportunities for investors with a high-risk tolerance. As prices come down, opportunities to invest in stocks trading at highly discounted valuations are increasingly cropping up.

″‘Buying the dip’ depends upon your timeframe,” says Richard Smith, CEO of investing tool RiskSmith. “If you can keep your money in the markets for at least a couple of years, this is a good dip to buy. You’ll likely be disappointed if you’re banking on the market reversing [soon] and heading back up to new highs.”

Although it’s unclear if the stock sell-off will steepen in the weeks to come, there are exceptionally safe, historically inexpensive, time-tested stocks worth buying on the dip. In line with Warren Buffett’s strategy of pursuing opportunities when there is a blood bath, the best stocks in a shaky market will always be those with a rare combination of quality and healthy potential for growth.

Our Methodology

To curate the list of the 11 best-falling stocks to buy according to analysts, we used the Finviz stock screener. We defined falling stocks as those trading within 0% to 10% of their 52-week lows. Using the Finviz stock screener, we got an aggregated list of stocks that fit our criteria. Next, we ranked these stocks in ascending order based on analysts’ upside potential (as of May 2). We have also mentioned the hedge fund sentiment around each stock, as of Q4 2024.

At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

11 Best-Falling Stocks to Buy According to Analysts

11. Healthpeak Properties, Inc. (NYSE:DOC)

52 Week Range: $17.33 – $23.26

Current Share Price: $17.78

Analysts Upside Potential as of May 2: 31.73%

Number of hedge fund holders: 37

Healthpeak Properties, Inc. (NYSE:DOC) is a healthcare real estate investment trust (REIT). It owns, operates, and develops real estate properties primarily for healthcare-tailored facilities. While the stock has pulled back significantly to the brink of its 52-week low, it is one of the best-falling stocks to buy, according to analysts, for gaining exposure in the real estate sector.

Likewise, analysts at Baird maintained an Outperform rating on Healthpeak Properties, Inc. (NYSE:DOC) even after cutting the price target to $22 from $24 on April 29. The bullish stance stems from the company offering an enticing 6.49% dividend yield, affirming its commitment to shareholder value. In addition, it delivered solid Q1 2025 results that beat analysts’ expectations. Earnings per share totaled $0.06 against $0.0519 expected. Revenue totaled $702.89 million against $683.39 million expected.

Healthpeak Properties, Inc. (NYSE:DOC) affirmed its ability to generate stable income and return value to shareholders in the long run by executing 1.2 million square feet of new and renewal leases. As of the end of Q1, its medical leases stood at 973,000 square feet and lab leases at 276,000 square feet. The company has also entered into a long-term partnership with Hines for a multifamily component in Massachusetts, further strengthening its footprint.

10. Avantor, Inc. (NYSE:AVTR)

52 Week Range: $12.20 – $28

Current Share Price: $12.96

Analysts Upside Potential as of May 2: 32.64%

Number of hedge fund holders: 39

Avantor, Inc. (NYSE:AVTR) is a medical instruments and supplies company that provides mission-critical products and services to customers in biopharma, healthcare, education, and government sectors. Its stock has been under pressure, going by the 38% year-to-date slide. On April 28, RBC Capital reiterated a Buy rating on the stock but cut the price target to $20.

On April 25, Avantor, Inc. (NYSE:AVTR) delivered mixed first-quarter 2025 results. While adjusted earnings per share came in at 23 cents better than the 22 cents a share delivered the same quarter last year, revenue fell 5.9% year-over-year to $1.58 billion. The sales slump was fueled by an 8% drop in the Laboratory Solutions segment, which was impacted by lower demand.

The stock remains under pressure on the confirmation that CEO Michael Stubblefield is stepping down and a cut to the guidance. The company expects organic revenue to range between 1% and -1%, down from the previous guidance of 1% to 3%. It also expects EBITDA margin to range between 17.5% and 18.5%, down from an initial guidance of 18% to 19%. Avantor, Inc. (NYSE:AVTR) has reviewed its full-year outlook to reflect funding and policy-related headwinds. Nevertheless, the company has also moved to strengthen its Lab solution segment. It also plans to cut operational costs by $400 million by 2027.

9. Thermo Fisher Scientific Inc. (NYSE:TMO)

52 Week Range: $409.85 – $627.88

Current Share Price: $419.89

Analysts Upside Potential as of May 2: 34.07%

Number of hedge fund holders: 100

Thermo Fisher Scientific Inc. (NYSE:TMO) is a diagnostics and research company that provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products. It provides reagents, instruments, and consumables for biological and medical research. Its stock has pulled back significantly after a 17% year-to-date slide, leaving it close to its 52-week low.

Amid the slump, Thermo Fisher Scientific Inc. (NYSE:TMO) is still one of the best-falling stocks to buy according to analysts. Despite cutting its price target to $470 from $620, analysts at Argus Research maintain a Buy rating on the stock. The Buy stance comes on the backdrop of Thermo Fisher Scientific unveiling an enhanced technology platform and a new CHO K-1 cell line. The two promise to reduce the investigational New Drug filing timelines from 13 months to nine. The new system is also poised to enable a new era of biologics drug development.

In addition, Thermo Fisher Scientific Inc. (NYSE:TMO) has inked a strategic partnership with RoosterBio, a leading supplier of adult human mesenchyme stem/stromal cells (hMSCs). The two are joining forces to accelerate the development of new potentially lifesaving cell and exosome therapies as they seek to tap growth opportunities in treating degenerative diseases.